Khalid Shah, Vice Chair of Research at Brigham and Women’s Hospital, Director of Center for Stem Cell and Translational Immunotherapy at Brigham and Women’s Hospital, Professor at Harvard Medical School, shared a post on LinkedIn:
“Excited to share our latest paper in Cancer Cell: ‘Overcoming functional and translational challenges of cellular immunotherapies for solid tumors’
Cell therapies have transformed outcomes in hematologic malignancies, but replicating this success in solid tumors remains a major challenge. In this review, we analyze the biological and clinical barriers underlying this gap and outline strategies to overcome them.
Our central argument is that examining different cellular therapies through a unified lens provides a clearer framework for understanding both current limitations and the trajectory of the field. This cross-platform perspective helps predict where cellular therapies are headed and how they must evolve. Looking ahead, the progress will depend on engineering smarter, self-regulating cellular therapies rather than simply more potent ones.
Congratulations to Yi-Ching Chen and Kok Siong Chen from our Center for Stem Cell and Translational Immunotherapy, MGB Neurosurgery, Harvard Stem Cell Institute. Grateful to collaborate with Bruce Levine from the University of Pennsylvania and excited about what lies ahead for the field.”
Title: Overcoming functional and translational challenges of cellular immunotherapies for solid tumors
Authors: Yi-Ching Chen, Kok-Siong Chen, Bruce Levine, Khalid Shah
Read the Full Article.
Other articles about Immunotherapy on OncoDaily.